Convergent Therapeutics is a clinical-stage biotechnology company in Cambridge, Massachusetts developing next-generation targeted radiotherapies for cancer. Its lead candidate, CONV01-α, is a PSMA-targeted monoclonal antibody linked to the alpha-emitting radioisotope actinium-225, designed to deliver tumor-killing radiation to metastatic castration-resistant prostate cancer while sparing healthy tissue. The technology, pioneered in the lab of PSMA-targeting pioneer Dr. Neil Bander and licensed from Cornell University, is led by oncologist Dr. Philip Kantoff.
Promaxo builds the world's first single-sided, in-office MRI platform - a compact magnet, AI, and robotics stack that lets urologists run image-guided prostate biopsies and focal treatments in their own clinic, without a hospital scanner suite.
Dr. Prithipal S. Sethi is a board-certified urologist, founder and CEO of Golden State Urology, and Chief Medical Officer at Promaxo - the company pioneering in-office MRI technology for prostate cancer diagnosis and treatment. With over 25 years of clinical practice, 2,500+ enlarged prostate procedures performed, and a career rooted in bringing advanced imaging technology directly into the urologist's office, Sethi straddles the worlds of clinical medicine and medical device innovation. Trained at UC Berkeley, St. Louis University, and Medical College of Wisconsin, he built Golden State Urology from a single Stockton practice in 2004 into a multi-location Northern California institution, and now serves as a clinical voice for a technology that is reshaping how prostate cancer is caught and treated.
Andre Esteva, PhD, is the co-founder and CEO of ArteraAI, a medical AI company whose test for personalizing prostate cancer therapy is included in NCCN clinical guidelines, reimbursed by Medicare, and deployed internationally. A Stanford-trained AI scientist whose Nature cover paper first demonstrated that AI could match dermatologists at diagnosing skin cancer, Esteva has co-founded four companies with a combined market cap of $2.2B. Named to TIME100 Health 2025 and Modern Healthcare's 40 Under 40 for 2025, he leads a company that raised $175M total and was named a TIME 2024 Best Invention.